Save Product
Product Details
-
Synonym
Spike,S protein,Spike glycoprotein,S glycoprotein
-
Source
SARS-CoV-2 S protein, His Tag, Super stable trimer (SPN-C52H9) is expressed from human 293 cells (HEK293). It contains AA Val 16 - Pro 1213 (Accession # QHD43416.1). The recombinant protein is expressed from human 293 cells (HEK293) with T4 fibritin trimerization motif and a polyhistidine tag at the C-terminus. Proline substitutions (F817P, A892P, A899P, A942P, K986P, V987P) and alanine substitutions (R683A and R685A) are introduced to stabilize the trimeric prefusion state of SARS-CoV-2 S protein and abolish the furin cleavage site, respectively.
Predicted N-terminus: Val 16Request for sequence -
Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus
The protein has a calculated MW of 138.0 kDa. The protein migrates as 150-200 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation. -
Endotoxin
Less than 1.0 EU per μg by the LAL method.
-
Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS. -
Formulation
Lyophilized from 0.22 μm filtered solution in 0.1 M Sodium citrate, pH5.5 with trehalose as protectant.
Contact us for customized product form or formulation. -
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA. -
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
-
ACRO Quality Management System
Customers Also Viewed
Performance Data
-
SDS-PAGE
SARS-CoV-2 S protein, His Tag, Super stable trimer on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
-
SEC-MALS
The purity of SARS-CoV-2 S protein, His Tag, Super stable trimer(Cat. No. SPN-C52H9) is more than 90% and the molecular weight of this protein is around 480-550 kDa verified by SEC-MALS.
Report
-
Negative Staining Electron Microscopy
The well-folded trimeric particles of this product was verified by negative stain electron micrography.
-
Bioactivity-ELISA
Immobilized Human ACE2, Fc Tag (Cat. No. AC2-H5257) at 1 μg/mL (100 μL/well) can bind SARS-CoV-2 S protein, His Tag, Super stable trimer (Cat. No. SPN-C52H9) with a linear range of 1-39 ng/mL (QC tested).
Protocol -
Immobilized Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 (Cat. No. SAD-S35) at 1 μg/mL (100 μL/well) can bind SARS-CoV-2 S protein, His Tag, Super stable trimer (Cat. No. SPN-C52H9) with a linear range of 0.2-3 ng/mL (Routinely tested).
Protocol -
Immobilized SARS-CoV-2 S protein, His Tag, Super stable trimer (Cat. No. SPN-C52H9) at 1 μg/mL (100 μL/well) can bind Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 (Cat. No. SAD-S35) with a linear range of 0.1-6 ng/mL (Routinely tested).
Protocol
-
Bioactivity-SPR
Human ACE2, Fc Tag (Cat. No. AC2-H5257) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind SARS-CoV-2 S protein, His Tag, Super stable trimer (Cat. No. SPN-C52H9) with an affinity constant of 40.9 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Protocol
Customer Reviews Writing Reviews
Background
Its been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.
Recent Advances
Drug Development Progress- English Name：
Coronavirus spike glycoprotein
- Category：
- Approved Drugs：
10 Details
- Drugs in Clinical Trials：
72 Details
- Highest Development Stage：
Approved
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing